Amgen "outperform"

09.03.07 - Robert W. Baird

NEW YORK, March 9 (newratings.com) - Analysts at Robert W Baird maintain their "outperform" rating on Amgen Inc (AMGN). The target price is set to $90.

In a research note published this morning, the analysts mention that a recent data query of some media records that were collected by Supportive Oncology Services suggests that Amgen?s claim that the usage of the Aranesp drug on the majority of chemotherapy patients is within the FDA-approved label appears to be completely accurate. According to the analysts, the tightening of the recommendation on Aranesp?s label by the FDA is unlikely to have any significant impact on the usage of the drug.